Last reviewed · How we verify

Capecitabine plus bevacizumab — Competitive Intelligence Brief

Capecitabine plus bevacizumab (Capecitabine plus bevacizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite plus monoclonal antibody. Area: Oncology.

phase 3 Antimetabolite plus monoclonal antibody Thymidylate synthase (capecitabine); VEGF (bevacizumab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Capecitabine plus bevacizumab (Capecitabine plus bevacizumab) — GERCOR - Multidisciplinary Oncology Cooperative Group. Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while bevacizumab is a monoclonal antibody that blocks VEGF to inhibit tumor angiogenesis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Capecitabine plus bevacizumab TARGET Capecitabine plus bevacizumab GERCOR - Multidisciplinary Oncology Cooperative Group phase 3 Antimetabolite plus monoclonal antibody Thymidylate synthase (capecitabine); VEGF (bevacizumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite plus monoclonal antibody class)

  1. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Capecitabine plus bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/capecitabine-plus-bevacizumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: